Sutro Biopharma prices 14.5M share offering at $5.18/share, raising ~$75M for research, development, and expansion.
Sutro Biopharma, a clinical-stage oncology firm, priced an underwritten offering of 14.5M shares at $5.18/share, raising around $75M before expenses. The funds will support research, clinical development, manufacturing, working capital, commercialization infrastructure, manufacturing expansion, acquisitions, investments, and other corporate purposes. Offering is expected to close on 4 April 2024, subject to conditions.
April 02, 2024
3 Articles